Abi-Saab Walid sold $1.4M of QURE

Abi-Saab Walid (Chief Medical Officer) sold 30,000 shares of uniQure N.V. (QURE) at an average of $46.42 ($46.40–$46.46, $1.39M total) across 2 trades on 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Abi-Saab Walid
Published Jul 2, 2026, 8:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QURE
Neutral
high confidence
Mentioned
$QURE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

The newest concrete fact is the disclosed sale size/value and execution date; it can marginally influence sentiment but provides no new information on uniQure’s pipeline, finances, or regulatory status.

02

Market read

Traders may note the insider sale for positioning/flow, but there is no fundamental catalyst in the filing text.

03

What to watch

The disclosure does not state motivations, and the price range ($46.40–$46.46) is not tied to any new company event in the text.

Relevance 5/10Novelty 3/10Timing: Filed 2026-07-02; sale executed 2026-06-30.

Background

The article is an SEC Form 4 insider transaction: uniQure N.V. (QURE) reported a sale by its Chief Medical Officer under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$QURENeutralHigh confidence
Context

uniQure’s CMO Abi-Saab Walid sold 30,000 shares in open-market transactions on 2026-06-30 under a 10b5-1 plan.

Expected impact

Low near-term impact; any effect is likely limited to sentiment/flow rather than a new catalyst.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan and no accompanying operational/regulatory/financial update.

Market effects

Limited read-through to biotech/rare-disease peers; this is company-specific insider activity without new clinical or regulatory data.

No clear regional spillover implied by the disclosure.

Minimal—no deal, trial, or regulatory event affecting broader markets is mentioned.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • uniQure N.V.

    Company that filed the Form 4 insider transaction disclosure.

  • Abi-Saab Walid

    Chief Medical Officer who sold 30,000 shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREMedAI 8/10

QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?

uniQure N.V. (QURE) shares rose 17.5% in a month, outperforming the industry and S&P 500. The rally was driven by FDA acceptance of its Huntington's disease drug application, ifezuntirgene inilparvovec, for review. Despite weaker Q3 2026 results, investors focus on the drug's potential. QURE's cash position is strong, with $768.4M as of Sept. 30, 2026, expected to fund operations through 2030.

$QUREMedAI 8/10

uniQure Prepares for Potential FDA Panel on Huntington’s Gene Therapy After Priority Review Nod

uniQure (QURE) is preparing for a potential FDA panel review of its gene therapy AMT-130 for Huntington's disease after receiving a priority review nod. The company presented 48-month data showing treated patients had less functional decline than untreated ones, though control group limitations were noted. uniQure plans a confirmatory study and is preparing for a potential launch, with $780 million in cash to fund operations into 2030.

$QUREHighAI 9/10

Key facts: AMT-130 Priority Review; 48-Month Data; Q3 Revenue +40%

uniQure's AMT-130 was accepted for FDA Priority Review with a decision goal of May 1, 2027. The U.K. validated its marketing application. 48-month data showed slowed Huntington’s disease progression. Q3 2026 revenue rose 40.4% to $5.2 million, below estimates, with net loss narrowing to $61.2 million. Cash reserves were $768.4 million.

MedAI 8/10

uniQure N.V. Q3 2026 Earnings Call Summary

uniQure N.V. reported that the FDA accepted its AMT-130 BLA with priority review for Huntington's disease, citing 36-month data showing a 60% slowing in TFC decline. The company plans a focused commercial launch targeting 15-30 priority institutions. Management expects the confirmatory study to be underway by the 2027 PDUFA date and cash runway to extend into 2030. SG&A expenses increased by $4.5 million year-over-year.

$QUREMed

uniQure (QURE) Q3 2026 Earnings Call Transcript

uniQure (QURE) reported progress in its Q3 2026 earnings call. The company's AMT-130 therapy for Huntington's disease showed a 75% slowing of disease progression in trials. The FDA is reviewing the Biologics License Application (BLA) with a PDUFA date of May 1, 2027. uniQure is preparing for a potential U.S. launch in 2027 and advancing its pipeline, including studies for AMT-260 and AMT-191. The company is also building its commercial teams ahead of the planned launch.